DAIC

JANUARY 23, 2024

1,6 Until recently atherosclerosis has been thought of as the result of passive lipid accumulation in the vessel wall. However, the development of atherosclerosis is now known to be much more complex, with a key role for immune cells and inflammation in conjunction with hyperlipidemia and elevated LDL levels.7 Curr Opin Lipidol.

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Frontiers in Cardiovascular Medicine

JULY 1, 2024

Statins are the primary drugs for treating hyperlipidemia or atherosclerosis, yet some patients remain unresponsive to them, and pregnant women are prohibited from taking statins. IntroductionThe incidence of metabolic disorders during pregnancy is increasing year by year, with diseases including hypertension and hyperlipidemia.

Cholesterol 52

Cholesterol Pharmacology Atherosclerosis Cancer 52

Cardiometabolic Health Congress

OCTOBER 25, 2024

Keynote speaker and atherosclerosis expert Peter Libby, MD , captivated the audience with an update on his research into inflammation and atherosclerosis. He discussed therapeutic options not only for treating atherosclerosis but also for preventing cardiovascular disease. Experts like Louis J.

CME 64

CME Innovation Education Atherosclerosis 64

Hypertension Journal

FEBRUARY 6, 2024

Aortic diseases such as atherosclerosis, aortic aneurysms, and aortic stiffening are significant complications that can have significant impact on end-stage cardiovascular disease. Hypertension, Ahead of Print.

Aortic 40

Aortic Atherosclerosis Pharmacology Aneurysm 40

Frontiers in Cardiovascular Medicine

MARCH 4, 2024

The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide.

Plaque 59

Plaque Coronary Artery Disease Blood Pressure Cardiovascular Disease 59

Dr. Paddy Barrett

APRIL 5, 2024

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. 2004 Mar 3;291(9):1071-80. 4 ASTEROID Investigators. 2006 Apr 5;295(13):1556-65.

Heart Disease 119

Heart Disease Coronary Artery Disease Heart Attack Heart attacks 119

DAIC

MAY 16, 2024

PAD is a serious, progressive cardiovascular disease primarily caused by a buildup of fatty plaque in the blood vessels, or atherosclerosis. Pharmacological and behavioral-based strategies often increase the smoking cessation rate in people with PAD, however, these strategies are underused.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

Journal of Cardiovascular Pharmacology

FEBRUARY 28, 2024

Atherosclerosis is an insidious and progressive inflammatory disease characterized by the formation of lipid-laden plaques within the intima of arterial walls with potentially devastating consequences.

Plaque 40

Plaque Thrombosis Atherosclerosis Article 40

Journal of Cardiovascular Pharmacology

SEPTEMBER 4, 2023

Dysregulation of the innate and adaptive immune system is accelerated by CKD and results in increased systemic inflammation, a heightened local vascular inflammatory response leading to accelerated atherosclerosis, and dysfunction of the cardiac and renal endothelium and microcirculation.

Kidney Disease 40

Kidney Disease Transplant Atherosclerosis Biomarkers 40

DAIC

FEBRUARY 7, 2024

His main career interests are in improving treatments for patients with intracranial arterial atherosclerosis and helping to mentor the next generation of clinical and translational scientists. The Ralph L. Raed Joundi, M.D., is the Vascular Cognitive Impairment Award recipient.

Stroke 105

Stroke Strokes Research Health Disparities 105

Frontiers in Cardiovascular Medicine

FEBRUARY 12, 2025

Then, we collected literature-validated TMYXP blood component targets for further network pharmacology analysis.ResultsAll blood components of TMYXP exhibited non-toxic properties. This study focused on peripheral blood mononuclear cell samples from 6 elderly patients with CHD over 60 years old (GSE142008).

Pharmacology 52

Pharmacology Heart Disease Atherosclerosis Risk Factors 52

Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2025

Analysis indicated that the 9 hub genes (AKT1, HSP90AA1, SRC, GSK3, VEGFR2, RHOA, ENO1, PKM, and IL-2) play roles in MF treatment by participating in signaling pathways related to prostate cancer, lipid and atherosclerosis, and insulin resistance.

Pharmacology 40

Pharmacology Atherosclerosis Biomarkers Cancer 40